You can see a variety of products from UNIMED
| Name | Lectacin Injection |
|---|---|
| Indications | 1. Effective bacteria Enterococci, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Hymophilus parainfluenza, Klebsiella pneumoniae, Moraxella catarrhalis, Proteus mirabilis, Pseudomonas aeruginosa, Serratia marcea sensus, Chlamydia pneumoniae, Legionella pneumoniae, Mycoplasma pneumoniae 2. Indications -Community-acquired pneumonia -Complex urinary tract infections, including acute pyelonephritis -Complex infections of the skin and soft tissues -Acute sinusitis -Acute bacterial exacerbation of chronic bronchitis Since fluoroquinolones, including this drug, are associated with serious adverse reactions, it is used for patients with acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and complicated skin and soft tissue infections for whom no other treatment options are available. |
Lectacin Injection
Per ml,
Levofloxacin anhydrous 5.0mg, levofloxacin hydrate 5.1246mg
1. Effective bacteria
Enterococci, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Hymophilus parainfluenza, Klebsiella pneumoniae, Moraxella catarrhalis, Proteus mirabilis, Pseudomonas aeruginosa, Serratia marcea sensus, Chlamydia pneumoniae, Legionella pneumoniae, Mycoplasma pneumoniae
2. Indications
-Community-acquired pneumonia
-Complex urinary tract infections, including acute pyelonephritis
-Complex infections of the skin and soft tissues
-Acute sinusitis
-Acute bacterial exacerbation of chronic bronchitis
Since fluoroquinolones, including this drug, are associated with serious adverse reactions, it is used for patients with acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and complicated skin and soft tissue infections for whom no other treatment options are available.
The treatment period varies depending on the progress of the disease. In general, administration of this drug (injection or tablet) should be continued for at least 48-72 hours after the patient is defervescent or evidence of eradication is obtained.
10V